Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Clasificación en acciones #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Precio por acción
$206.50
Capitalización bursátil
$365.13B
Cambio (1 día)
-0.31%
Cambio (1 año)
2.58%
País
US
Comercio AbbVie Inc. (ABBV)

Categoría

Margen Operativo de AbbVie Inc. (ABBV)
Margen Operativo al March 2026 TTM: 26.72%
Según los informes financieros más recientes y el precio de las acciones de AbbVie Inc., el margen operativo actual (TTM) es 26.72%. Al final de 2024, el margen operativo era 16.22%.
Historial de Margen Operativo de AbbVie Inc. desde 2009 hasta 2026
Margen Operativo al final de cada año
Año Margen Operativo Cambiar
2026 (TTM) 26.72% -22.97%
2025 34.69% 113.87%
2024 16.22% -30.95%
2023 23.49% -24.74%
2022 31.21% -2.13%
2021 31.89% 28.54%
2020 24.81% -36.43%
2019 39.03% 100.26%
2018 19.49% -42.39%
2017 33.83% -7.14%
2016 36.43% 10.49%
2015 32.97% 92.92%
2014 17.09% -43.30%
2013 30.14% -4.77%
2012 31.65% 52.53%
2011 20.75% -31.20%
2010 30.16% -13.08%
2009 34.70% 0.00%
Margen Operativo de empresas similares o competidoras
Empresa Margen Operativo Diferencia de Margen Operativo País
45.56% -98.29%
US
23.28% -99.13%
GB
27.17% -98.98%
US
31.24% -98.83%
CH
41.19% -98.46%
US
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.